TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Brainsway Ltd.
BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

BrainsWay received FDA clearance to use Deep TMS™ as an adjunct therapy for major depressive disorder in adolescents aged 15-21, based on a comprehensive dataset of 1,120 patients showing significant symptom improvement and safety.

Insights
NVO   negative

Accused of making an illegal acquisition attempt with potential regulatory risks and deliberate antitrust evasion


BWAY   positive

Company achieved significant regulatory milestone expanding treatment options for adolescent depression, demonstrating clinical efficacy and expanding market reach